Trials / Completed
CompletedNCT05941442
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to measure the efficacy, safety, and tolerability of darigabat (25 milligrams \[mg\] twice daily \[BID\]) compared with placebo in participants with panic disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darigabat | Oral tablets |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2023-07-31
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
- First posted
- 2023-07-12
- Last updated
- 2025-04-04
Locations
31 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05941442. Inclusion in this directory is not an endorsement.